These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 31996269)

  • 21. A novel mutation of α-galactosidase A gene causes Fabry disease mimicking primary erythromelalgia in a Chinese family.
    Ge W; Wei B; Zhu H; Miao Z; Zhang W; Leng C; Li J; Zhang D; Sun M; Xu X
    Int J Neurosci; 2017 May; 127(5):448-453. PubMed ID: 27211852
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Fabry disease screening in high-risk populations in Japan: a nationwide study.
    Yoshida S; Kido J; Sawada T; Momosaki K; Sugawara K; Matsumoto S; Endo F; Nakamura K
    Orphanet J Rare Dis; 2020 Aug; 15(1):220. PubMed ID: 32843101
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Identification of a Novel GLA Gene Mutation, p.Ile239Met, in Fabry Disease With a Predominant Cardiac Phenotype.
    Csányi B; Hategan L; Nagy V; Obál I; Varga ET; Borbás J; Tringer A; Eichler S; Forster T; Rolfs A; Sepp R
    Int Heart J; 2017 May; 58(3):454-458. PubMed ID: 28496025
    [TBL] [Abstract][Full Text] [Related]  

  • 24. An intronic haplotype in α galactosidase A is associated with reduced mRNA expression in males with cryptogenic stroke.
    Zeevi DA; Hakam-Spector E; Herskovitz Y; Beeri R; Elstein D; Altarescu G
    Gene; 2014 Oct; 549(2):275-9. PubMed ID: 25101867
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Increased glycolipid storage produced by the inheritance of a complex intronic haplotype in the α-galactosidase A (GLA) gene.
    Gervas-Arruga J; Cebolla JJ; Irun P; Perez-Lopez J; Plaza L; Roche JC; Capablo JL; Rodriguez-Rey JC; Pocovi M; Giraldo P
    BMC Genet; 2015 Sep; 16():109. PubMed ID: 26334996
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Genotype-phenotype analysis of Fabry disease caused by GLA gene variation in a pedigree].
    Ge ZH; Lu ZH; Pan XD; Lai TT; Yang MJ; Yang HQ; Zhang HB; Li GY; Dai ZQ; Mao JH
    Zhonghua Er Ke Za Zhi; 2024 Mar; 62(4):345-350. PubMed ID: 38527505
    [No Abstract]   [Full Text] [Related]  

  • 27. Frequency of Fabry disease in male and female haemodialysis patients in Spain.
    Gaspar P; Herrera J; Rodrigues D; Cerezo S; Delgado R; Andrade CF; Forascepi R; Macias J; del Pino MD; Prados MD; de Alegria PR; Torres G; Vidau P; Sá-Miranda MC
    BMC Med Genet; 2010 Feb; 11():19. PubMed ID: 20122163
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Screening for Fabry Disease in patients with unexplained left ventricular hypertrophy.
    Sadasivan C; Chow JTY; Sheng B; Chan DKH; Fan Y; Choi PCL; Wong JKT; Tong MMB; Chan TN; Fung E; Kam KKH; Chan JYS; Chi WK; Paterson DI; Senaratne M; Brass N; Oudit GY; Lee APW
    PLoS One; 2020; 15(9):e0239675. PubMed ID: 32987398
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Fabry disease presenting as apical left ventricular hypertrophy in a patient carrying the missense mutation R118C.
    Caetano F; Botelho A; Mota P; Silva J; Leitão Marques A
    Rev Port Cardiol; 2014 Mar; 33(3):183.e1-5. PubMed ID: 24661928
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prevalence of Fabry disease in a predominantly hypertensive population with left ventricular hypertrophy.
    Terryn W; Deschoenmakere G; De Keyser J; Meersseman W; Van Biesen W; Wuyts B; Hemelsoet D; Pascale H; De Backer J; De Paepe A; Poppe B; Vanholder R
    Int J Cardiol; 2013 Sep; 167(6):2555-60. PubMed ID: 22805550
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparing the alpha-galactosidase A biochemical properties from healthy individuals and Fabry disease patients.
    Daitx VV; Mezzalira J; Moraes Vda C; Breier AC; Cé J; Coelho JC
    Clin Chim Acta; 2015 May; 445():60-4. PubMed ID: 25804996
    [TBL] [Abstract][Full Text] [Related]  

  • 32. First phenotypic description of a female patient with c.610 T > C variant of GLA: a renal-predominant presentation of Fabry disease.
    Greillier S; Daniel L; Caillaud C; Dussol B; Touchard G; Goujon JM; Jourde-Chiche N; Bobot M
    BMC Med Genet; 2020 Jun; 21(1):137. PubMed ID: 32590976
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Functional and pharmacological evaluation of novel GLA variants in Fabry disease identifies six (two de novo) causative mutations and two amenable variants to the chaperone DGJ.
    Ferri L; Malesci D; Fioravanti A; Bagordo G; Filippini A; Ficcadenti A; Manna R; Antuzzi D; Verrecchia E; Donati I; Mignani R; Cavicchi C; Guerrini R; Morrone A
    Clin Chim Acta; 2018 Jun; 481():25-33. PubMed ID: 29476735
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Detection of novel Fabry disease-associated pathogenic variants in Japanese patients by newborn and high-risk screening.
    Sawada T; Kido J; Sugawara K; Matsumoto S; Takada F; Tsuboi K; Ohtake A; Endo F; Nakamura K
    Mol Genet Genomic Med; 2020 Nov; 8(11):e1502. PubMed ID: 33016649
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Alpha-Galactosidase A p.A143T, a non-Fabry disease-causing variant.
    Lenders M; Weidemann F; Kurschat C; Canaan-Kühl S; Duning T; Stypmann J; Schmitz B; Reiermann S; Krämer J; Blaschke D; Wanner C; Brand SM; Brand E
    Orphanet J Rare Dis; 2016 May; 11(1):54. PubMed ID: 27142856
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Fabry disease due to D313Y and novel GLA mutations.
    Koulousios K; Stylianou K; Pateinakis P; Zamanakou M; Loules G; Manou E; Kyriklidou P; Katsinas C; Ouzouni A; Kyriazis J; Speletas M; Germenis AE
    BMJ Open; 2017 Oct; 7(10):e017098. PubMed ID: 28988177
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Functional Characterization and Pharmacological Evaluation of a Novel GLA Missense Mutation Found in a Severely Affected Fabry Disease Family.
    Varela P; Mastroianni Kirsztajn G; Ferrer H; Aranda C; Wallbach K; Ferreira da Mata G; Moura LA; Moreira SR; Mendes C; Curiati MA; Martins AM; Bosco Pesquero J
    Nephron; 2020; 144(3):147-155. PubMed ID: 31665721
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prevalence of Fabry disease-causing variants in the UK Biobank.
    Gilchrist M; Casanova F; Tyrrell JS; Cannon S; Wood AR; Fife N; Young K; Oram RA; Weedon MN
    J Med Genet; 2023 Apr; 60(4):391-396. PubMed ID: 35977816
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Analysis of the alpha galactosidase gene: mutation profile and description of two novel mutations with extensive literature review in Turkish population.
    Onay H; Bolat H; Kılıç Yıldırım G; Kose E; Kalkan Uçar S; Aşıkovalı S; Özkınay F; Çoker M
    J Pediatr Endocrinol Metab; 2020 Aug; 33(10):1245-1250. PubMed ID: 32813676
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Unbalanced GLA mRNAs ratio quantified by real-time PCR in Fabry patients' fibroblasts results in Fabry disease.
    Filoni C; Caciotti A; Carraresi L; Donati MA; Mignani R; Parini R; Filocamo M; Soliani F; Simi L; Guerrini R; Zammarchi E; Morrone A
    Eur J Hum Genet; 2008 Nov; 16(11):1311-7. PubMed ID: 18560446
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.